Exploristics and Exonate announce successful KerusCloud collaboration

Exploristics and Exonate announce successful KerusCloud collaboration

Exploristics and Exonate announce successful KerusCloud collaboration 260 200 Exploristics

Exploristics and Exonate announce successful collaboration optimising study design with KerusCloud for Exonate’s upcoming Phase IIb study.

Exploristics and Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, are delighted to announce the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease. The collaboration has supported ongoing development of Exonate’s lead candidate, EXN407, following a recent successful Phase Ib/IIa study in November.


Using Exploristics’ innovative simulation guided clinical trial design platform, KerusCloud, the companies established a more efficient, data-driven approach to study design and protocol development within Exonate’s clinical development programs in retinal vascular diseases. KerusCloud was successful in delivering valuable quantitative insights into the upcoming clinical study, enabling an enhanced study design that minimises the risks, cost and duration of the programme.


The Phase IIb study is planned to initiate in 2024, following the successful completion of the Company’s Phase Ib/IIa trial for EXN407. The study concluded that EXN407 met all pharmacokinetic and safety parameters, as well as showing encouraging signs of biological activity. For more information, please see the press release announced on 5th March 2024.


Aiden Flynn, CEO, Exploristics, said:We are delighted to have had the opportunity to work with Exonate to harness KerusCloud’s powerful and realistic simulations to ensure that the company’s clinical trial was primed for success. Exonate recognised the need to implement a data-driven approach to optimise efficiency and minimise the risks of their proof-of-concept studies by using rational design to manage key uncertainties and challenges. We look forward to a continuation of the relationship as Exonate progresses to Phase IIb clinical trials in 2024.


Loic Lhuillier, COO of Exonate commented: “We were pleased to partner with the Exploristics team on our trial design and statistical analysis, which has greatly contributed to the efficiency of the programme. KerusCloud allowed us to develop our study design to recognise the transformative potential of EXN407 whilst ensuring we account for and minimise any potential risks. We thank Aiden and the team for their collaborative model and expertise throughout this project.”


To stay up to date on the development process of Exonate’s retinal vascular disease treatments, visit: https://www.exonate.com/

Aiden Flynn, CEO, Exploristics

Loic Lhuillier, COO, Exonate

For further information please contact:



Aiden Flynn, PhD

Tel: +44 28 9600 1996

Email: aiden.flynn@exploristics.com


Zyme Communications

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: katie.odgaard@zymecommunications.com


To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.


About Exploristics

Exploristics is a technology-enabled services company that transforms clinical development for life science organisations with unique proprietary software and biostatistics consultancy supporting the planning, design and analysis of clinical studies. For more information about Exploristics, visit www.exploristics.com or follow us on LinkedIn or X.

About KerusCloud

KerusCloud is Exploristics’ revolutionary simulation-guided study design platform that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development timelines, costs and patient burden. To do this, KerusCloud uses real clinical information to generate highly realistic synthetic data sets (virtual populations). These synthetic data are then used as the basis for generating high numbers of study simulations that accurately mimic the complexity of real clinical studies. This allows researchers to assess the performance of multiple study design and analysis scenarios in silico, in minutes and choose the best options for real studies, first time.

For more information on KerusCloud, please visit https://exploristics.com/keruscloud-platform-overview/ or read our case studies.

About Exonate

Exonate is a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases which may lead to vision loss.

The Company’s pipeline is built around inhibition of pro-angiogenic VEGF by influencing splice patterns, for the treatment of conditions that have the formation of new blood vessels as a significant contributor, such as wet Age-Related Macular Degeneration (wet AMD) and Diabetic Macular Oedema (DME). Developed to penetrate to the back of the eye, reach the retina and prevent growth of blood vessels, Exonate’s treatments for retinal diseases are being developed as eye drops, eliminating the need for monthly injections into the eye, laser surgery or use of steroids, without sacrificing potency or permeability.

There is a large unmet market opportunity for a topical therapy for diabetic retinopathy and diabetic macular oedema that can treat the conditions earlier in the disease process. Exonate’s lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. EXN407 has shown encouraging signs of efficacy, alongside meeting all endpoints, in a Phase Ib/IIa trial in diabetic patients with retinal eye disease (diabetic macular oedema).

The Company is led by a highly experienced management team, and has a strong foundation of scientific expertise, with cross-disciplinary experience in medicine and drug development.

For more information, visit the Exonate website, or find Exonate on X (@ExonateUK) and LinkedIn (@ Exonate Limited).